Table of Contents
Understanding Respiratory Syncytial Virus (RSV)
Respiratory syncytial virus (RSV) is a prominent cause of illness, particularly in young children. It is the leading reason for infant hospitalizations, responsible for approximately 3 million hospitalizations and over 100,000 deaths annually in children under the age of 5. This global health challenge calls for effective prevention methods and treatments to reduce the disease burden and protect our youngest population.
New Prevention Methods: Nirsevimab and Abrysvo
Recent advances in medicine have introduced two new prevention methods: nirsevimab and Abrysvo. Nirsevimab is a monoclonal antibody that provides direct combat against the virus, while Abrysvo is a new immunization provided to pregnant patients. Both methods have demonstrated effectiveness and safety in clinical trials. Nirsevimab has been shown to reduce severe disease and hospitalization from RSV by a staggering 80%, while Abrysvo leads to a 57% decrease in the chance of infant hospitalization due to RSV.
Availability and Recommendations
The availability of nirsevimab is currently limited, prioritizing newborn children in Neonatal Intensive Care Units (NICUs), while Abrysvo is more accessible at obstetrician offices and local Walgreens pharmacies. The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics recommend that the RSV vaccine be given during the first 8 months of life to protect infants when they are most vulnerable to the serious illness caused by the virus.
Additional Insights
Nirsevimab, approved by the U.S. Food and Drug Administration (FDA), inhibits RSV from fusing to cellular membranes, significantly reducing the health and economic burdens of RSV. It has potential adverse effects and contraindications and requires professional administration, underscoring the importance of nursing practice in its application.
Strategic timing of the administration of monoclonal antibodies like nirsevimab can also have significant impacts on the prevention of RSV-associated hospitalizations. For instance, administering the antibody to children born from July to January at birth, and to the remaining under-1-year-old children in September or October, has been shown to maximize the number of averted RSV-ALRI hospitalizations and minimizes the number needed to treat (NNT).
New Tools and Vaccines for RSV Prevention
New tools and vaccines for preventing RSV among young children have been approved for use in the European Union. One notable development is nirsevimab, a long-acting monoclonal antibody, licensed for use in infants at the end of 2022. Spain and France have already included nirsevimab in their national immunization programs, with early uptake exceeding expectations.
In addition to nirsevimab, Abrysvo is recommended for pregnant individuals who are 32 through 36 weeks pregnant from September through January. Abrysvo protective antibodies pass to the baby over the course of about two weeks when a pregnant person gets the RSV vaccine. This immunization method has shown a significant decrease in the chance of infant hospitalization due to RSV.
Conclusion
The developments in RSV prevention offer a beacon of hope in the fight against one of the most common causes of hospitalization and death in infants and young children. The CDC’s Advisory Committee on Immunization Practices and the American Academy of Pediatrics recommend that the RSV vaccine be given during the first 8 months of life to protect infants when they are most vulnerable to serious illness from this virus. The advent of nirsevimab and Abrysvo is a significant stride forward in this cause, promising a healthier future for our children.
